Clinical Orthopaedics and Related Research: December 2013 - Volume 471 - Issue 12 - p 3891–3900 doi: 10.1007/s11999-013-2929-3 Symposium: 2012 International Hip Society Proceedings

Low Rate of Dislocation of Dual-mobility Cups in Primary Total Hip Arthroplasty

Combes, Antoine, MD1; Migaud, Henri, MD1, a; Girard, Julien, MD, PhD1; Duhamel, Alain, PhD2; Fessy, Michel, Henri, MD, PhD3

Background Dual-mobility (DM) cups were introduced to minimize the risk of THA dislocation. The overall rate of dislocation of DM cups (including both large and small articulations) is controversial and ranges from 0% to 5% in previous studies.


Questions/purposes We therefore recorded (1) the dislocation rate, (2) loosening and osteolysis, and (3) subsequent related revisions with DM cups.


Methods Between 1998 and 2003, 2480 primary THAs with DM cups were undertaken in 2179 patients. The mean age was 69 years (range, 19-94 years). This group underwent specific clinical and radiographic evaluation at a minimum followup of 0.17 years (mean, 7 years; range, 0.17-11 years) to assess dislocation, reoperation, osteolysis, and cup fixation.


Results There were 22 dislocations (0.88%): 15 dislocations of large articulations (0.6%), with two (0.08%) recurring but only one requiring revision (0.04%), and seven intraprosthetic small articulation dislocations (0.28%), all needing revision surgery. At last followup, mean Harris hip score was 91 (range, 60-100); 2439 cups (98%) showed no signs of loosening; and 141 patients (145 hips) had osteolysis (6%). Osteolysis and cup loosening were more frequent in patients younger than 50 years at the time of surgery. The 10-year survivorship considering revision for any reason was 93% (95% CI, 91%-95%).


Conclusions DM cups had a low dislocation rate in primary THA, with a limited frequency of adverse effects. We recommend DM cups to minimize dislocation in populations at high risk for instability, but they should be avoided in younger, active patients at higher risk for osteolysis.


Level of Evidence Level IV, therapeutic study. See Instructions for Authors for a complete description of levels of evidence.

Download article